3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Anemia
1
Amyloidosis
1
Interventions
Rituximab
4
Lenalidomide
2
Crizotinib
2
Bendamustine Hydrochloride
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
polatuzumab vedotin
1
pirtobrutinib
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
obinutuzumab
1
larotrectinib
1
ipatasertib
1
idelalisib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vincristine
1
Trastuzumab
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma
×
Cyclophosphamide
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA